Development of Scoring Functions for Antibody Sequence Assessment and Optimization

Antibody development is still associated with substantial risks and difficulties as single mutations can radically change molecule properties like thermodynamic stability, solubility or viscosity. Since antibody generation methodologies cannot select and optimize for molecule properties which are important for biotechnological applications, careful sequence analysis and optimization is necessary to develop antibodies that fulfil the ambitious requirements of future drugs. While efforts to grab the physical principles of undesired molecule properties from the very bottom are becoming increasingly powerful, the wealth of publically available antibody sequences provides an alternative way to develop early assessment strategies for antibodies using a statistical approach which is the objective of this paper. Here, publically available sequences were used to develop heuristic potentials for the framework regions of heavy and light chains of antibodies of human and murine origin. The potentials take into account position dependent probabilities of individual amino acids but also conditional probabilities which are inevitable for sequence assessment and optimization. It is shown that the potentials derived from human sequences clearly distinguish between human sequences and sequences from mice and, hence, can be used as a measure of humaness which compares a given sequence with the phenotypic pool of human sequences instead of comparing sequence identities to germline genes. Following this line, it is demonstrated that, using the developed potentials, humanization of an antibody can be described as a simple mathematical optimization problem and that the in-silico generated framework variants closely resemble native sequences in terms of predicted immunogenicity.

[1]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[2]  Peter M Bowers,et al.  An integrated approach to extreme thermostabilization and affinity maturation of an antibody. , 2013, Protein engineering, design & selection : PEDS.

[3]  P. Tessier,et al.  Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. , 2012, Protein engineering, design & selection : PEDS.

[4]  N. Lonberg Human antibodies from transgenic animals , 2005, Nature Biotechnology.

[5]  H. Hoogenboom,et al.  Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.

[6]  G. Gilliland,et al.  Structure-based engineering of a monoclonal antibody for improved solubility. , 2010, Protein engineering, design & selection : PEDS.

[7]  Andrew C. R. Martin,et al.  Accessing the Kabat antibody sequence database by computer , 1996, Proteins.

[8]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[9]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[10]  T. Arakawa,et al.  Mechanisms of protein aggregation. , 2009, Current pharmaceutical biotechnology.

[11]  D. Altschuh,et al.  Covariance analysis of protein families: The case of the variable domains of antibodies , 2000, Proteins.

[12]  Andreas Plückthun,et al.  Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. , 2004, Methods.

[13]  Eric T. Boder,et al.  Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.

[14]  Bernhardt L Trout,et al.  Prediction of aggregation prone regions of therapeutic proteins. , 2010, The journal of physical chemistry. B.

[15]  Brian M. Murphy,et al.  Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.

[16]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.

[17]  A. Plückthun,et al.  Transfer of engineered biophysical properties between different antibody formats and expression systems. , 2012, Protein engineering, design & selection : PEDS.

[18]  David Baker,et al.  Protein Structure Prediction Using Rosetta , 2004, Numerical Computer Methods, Part D.

[19]  Yvonne Stark,et al.  A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties , 2013, mAbs.

[20]  Thomas A. Hopf,et al.  Protein 3D Structure Computed from Evolutionary Sequence Variation , 2011, PloS one.

[21]  Thomas B. Kepler,et al.  Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody , 2012, Proceedings of the National Academy of Sciences.

[22]  Andrew C. R. Martin,et al.  Analyzing the "degree of humanness" of antibody sequences. , 2007, Journal of molecular biology.

[23]  Anne S De Groot,et al.  Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. , 2009, Clinical immunology.

[24]  Gregory A Voth,et al.  Coarse-grained modeling of the self-association of therapeutic monoclonal antibodies. , 2012, The journal of physical chemistry. B.

[25]  François Stricher,et al.  The FoldX web server: an online force field , 2005, Nucleic Acids Res..

[26]  Steven J Shire,et al.  Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.

[27]  D. Stock,et al.  General strategy for the generation of human antibody variable domains with increased aggregation resistance , 2012, Proceedings of the National Academy of Sciences.

[28]  R. Ranganathan,et al.  Evolutionarily conserved pathways of energetic connectivity in protein families. , 1999, Science.

[29]  P. Tessier,et al.  Engineering aggregation-resistant antibodies. , 2012, Annual review of chemical and biomolecular engineering.

[30]  Stefan M. Larson,et al.  Analysis of covariation in an SH3 domain sequence alignment: applications in tertiary contact prediction and the design of compensating hydrophobic core substitutions. , 2000, Journal of molecular biology.

[31]  John D. Hunter,et al.  Matplotlib: A 2D Graphics Environment , 2007, Computing in Science & Engineering.

[32]  Dmitrij Frishman,et al.  Co-evolving residues in membrane proteins , 2007, Bioinform..

[33]  D. Altschuh,et al.  Functional aspects of co‐variant surface charges in an antibody fragment , 2002, Protein science : a publication of the Protein Society.

[34]  William F Weiss,et al.  Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.

[35]  Bernhardt L Trout,et al.  Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. , 2012, Journal of pharmaceutical sciences.

[36]  N. Metropolis,et al.  Equation of State Calculations by Fast Computing Machines , 1953, Resonance.

[37]  Richard W. Aldrich,et al.  A perturbation-based method for calculating explicit likelihood of evolutionary co-variance in multiple sequence alignments , 2004, Bioinform..

[38]  L. Serrano,et al.  Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.

[39]  Richard W Aldrich,et al.  On Evolutionary Conservation of Thermodynamic Coupling in Proteins* , 2004, Journal of Biological Chemistry.